^
Association details:
| Biomarker: | FGFR2-OPTN fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Truseltiq (infigratinib) (FGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma
Excerpt:
...a 47 year old female who underwent a left hepatectomy for a 10.9 cm, T2N0 ICC, and received adjuvant chemotherapy...SFA testing on the liver metastasis revealed a different novel fusion, this time between FGFR2 exon 17 and the Optineurin (OPTN) exon 5. The patient was then enrolled in the BGJ398 trial, achieving a maximum response of -28% at 2 months...
DOI:
https://dx.doi.org/10.1158%2F2159-8290.CD-16-1000
